Vertex Pharmaceuticals (VRTX) Stock May Be 33% Undervalued Following New ALYFTREK Data

Vertex Pharmaceuticals has delivered a powerful long term share price run, yet the key issue for anyone looking at the stock today is whether its current US$510.08 level is supported by the cash flows the business can generate. With a Discounted Cash Flow (DCF) framework available, the spotlight is firmly on what those future cash streams suggest about intrinsic value versus the market quote.

• Over the past 5 years, Vertex Pharmaceuticals has delivered a 180.6% total return. This puts real pressure on investors to test whether that climb is grounded in its underlying cash generation.
• Fresh data from the ALYFTREK study in very young cystic fibrosis patients suggests Vertex Pharmaceuticals may see expectations shift around the duration and timing of treatment related cash flows, as earlier intervention can influence long term therapy use and value per patient.
• Prefer to judge Vertex Pharmaceuticals on earnings? See what Vertex Pharmaceuticals's 29.3x P/E says about the price.

The stock's next move may depend on whether the cash flows implied by Vertex Pharmaceuticals' Discounted Cash Flow (DCF) estimate line up with the price investors are paying today.

If you are weighing whether Vertex Pharmaceuticals' cash flows justify its price, it can help to compare that question across 29 high quality undervalued stocks.

Is Vertex Pharmaceuticals Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model here uses Vertex Pharmaceuticals' cash generation to anchor the discussion rather than short term headlines. Latest twelve month free cash flow sits around $3.79b, and the projections build in a growing stream of $ free cash flows over the coming decade rather than a shrinking one.

Those rising cash expectations, when discounted back, point to an estimated intrinsic value that the DCF suggests is substantially above the current $510.08 share price. Because the recent ALYFTREK data flags potential treatment use in very young cystic fibrosis patients, the market reaction to that news helps explain why investors are scrutinising how long this $ cash flow profile can last and whether the current quote already reflects it. Find out what Vertex Pharmaceuticals could be worth using our Discounted Cash Flow (DCF) estimate.

The Vertex Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Vertex Pharmaceuticals pick up exactly where this valuation puzzle leaves off, since they spell out which paths for revenue, margins and earnings would need to play out for the shares to trade materially above or below today's price, and they sit on Simply Wall St's Community page. Rather than leaning on a single multiple or model result, each narrative lays out the assumptions behind its fair value so you can line them up against Vertex Pharmaceuticals' reported numbers over time.

Vertex Pharmaceuticals inspires two sharply different interpretations of how much the current price already reflects its multi pillar plan.

Bull case: 11% undervalued

"Analysts expect Vertex Pharmaceuticals to expand beyond cystic fibrosis into five commercial pillars, with renal disease, endocrinology, hematology, pain and type 1 diabetes collectively supporting a more balanced revenue mix over time…"

Discover why this Narrative puts Vertex Pharmaceuticals at 11% undervalued.

Bear case: 18% overvalued

"The numbers on guidance, acquisitions, and pipeline scale imply a share price that already incorporates successful diversification beyond cystic fibrosis and strong long term execution, leaving limited room for disappointment…"

Explore why this Narrative puts Vertex Pharmaceuticals at 18% overvalued.

One more piece of the Vertex Pharmaceuticals puzzle worth checking

Cash flow projections only tell part of the story, because the people steering Vertex Pharmaceuticals and the way they are rewarded can reinforce or undermine everything investors see in the numbers. See who runs Vertex Pharmaceuticals and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com